#HVO hVIVO – H1 TRADING UPDATE July 22, 2025 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, provides an unaudited trading update for the six months ended 30 June 2025 (H1 2025). Highlights · Revenue of £24.2 million (H1 2024: £35.6 million), in line with expectations of £47 million for the full year · EBITDA margin (pre-exceptionals) of c.12% (H1 2024: 24.5%) · Cash of £23.3 million as at 30 June 2025 (30 June…

Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies December 7, 2020 – Posted in: Open Orphan (ORPH)

Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies Pharmaceutical companies worldwide are joining global efforts to combat, diagnose, treat and prevent infections from COVID-19. As we have seen, the search for vaccines and possible treatment to curb the transmission and reduce the mortality and morbidity produced by the virus is in overdrive. Link here to read the full article…

#HVO hVIVO – H1 TRADING UPDATE July 22, 2025 – Posted in: Blog, hVIVO (HVO)

Pharma Tech Article – Open Orphan #ORPH – Accelerated Vaccine Development with Human Challenge Studies December 7, 2020 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL